Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Marie Skłodowska-Curie Action · Running

VisionGuard Decoding retinal cell communication to counteract vision loss in aging

Coordinator
Aarhus Universitet, Denmark
Runs
1 May 2027 to 30 April 2029
Status
Running
EU funding
€263k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101263742

What the project is doing

In the project's own words, from its summary on CORDIS.

The retinal pigment epithelium (RPE) protects our vision through a wide array of essential functions, particularly by supporting the photoreceptors. With aging, the RPE undergoes stress that disrupts these functions and contributes to the development of age-related macular degeneration (AMD). AMD is the leading cause of vision loss in Europe and is projected to affect 77 million people in the EU by 2050.As the disease progresses, communication between the RPE and the underlying blood vessels becomes impaired.

The resulting pathological vessel growth marks the most severe stage of AMD, neovascular AMD. If left untreated, this stage leads to photoreceptor damage and vision loss. Current therapies are ineffective for a significant number of patients, highlighting the need for alternative approaches. To communicate effectively with photoreceptors and blood vessels, RPE cells must maintain an intracellular organization that enables the directional secretion of key signaling molecules.

This project aims to investigate the underlying disease mechanisms by exploring the mechanistic link between age-related changes in RPE cell morphology, intracellular trafficking and secretion dynamics, and pathological vessel growth. To this end, the project will integrate cutting-edge approaches. I will employ proteomics to analyze changes in RPE secretory profiles, develop an innovative in vitro screening platform to functionally assess candidate proteins for their signaling effects on blood vessels, and validate the therapeutic potential of top candidates in vivo using RNAi-based therapeutics and a mouse model of neovascular AMD.

Hosted at Aarhus University, in a leading lab for retinal gene therapy, and building on my expertise in epithelial polarity, in vitro modelling and siRNA screening, this project will provide impactful insights into retinal disease mechanisms and foster innovation in AMD treatment.

Topics

Who is involved

OrganisationCityCountryRole
Aarhus UniversitetAarhus CDenmarkCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI